<code id='EB2A2AA37F'></code><style id='EB2A2AA37F'></style>
    • <acronym id='EB2A2AA37F'></acronym>
      <center id='EB2A2AA37F'><center id='EB2A2AA37F'><tfoot id='EB2A2AA37F'></tfoot></center><abbr id='EB2A2AA37F'><dir id='EB2A2AA37F'><tfoot id='EB2A2AA37F'></tfoot><noframes id='EB2A2AA37F'>

    • <optgroup id='EB2A2AA37F'><strike id='EB2A2AA37F'><sup id='EB2A2AA37F'></sup></strike><code id='EB2A2AA37F'></code></optgroup>
        1. <b id='EB2A2AA37F'><label id='EB2A2AA37F'><select id='EB2A2AA37F'><dt id='EB2A2AA37F'><span id='EB2A2AA37F'></span></dt></select></label></b><u id='EB2A2AA37F'></u>
          <i id='EB2A2AA37F'><strike id='EB2A2AA37F'><tt id='EB2A2AA37F'><pre id='EB2A2AA37F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:leisure time    - browse:23
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot